Press coverage about Zai Lab (NASDAQ:ZLAB) has been trending positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zai Lab earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.1933989661353 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
A number of research firms recently weighed in on ZLAB. JPMorgan Chase & Co. upgraded Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price objective for the company in a report on Wednesday, February 14th. BidaskClub raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st.
Zai Lab (ZLAB) opened at $21.63 on Wednesday. Zai Lab has a 1 year low of $19.80 and a 1 year high of $35.74.
COPYRIGHT VIOLATION NOTICE: This article was originally published by BBNS and is the sole property of of BBNS. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://baseballnewssource.com/2018/03/14/favorable-news-coverage-somewhat-unlikely-to-impact-zai-lab-zlab-stock-price/1971170.html.
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.